There is no known immunosuppressive therapy for autoimmune premature ovarian failure that has been proven safe and effective by prospective randomized placebocontrolled study. Nevertheless, immunosuppression using corticosteroids has been used on an empirical basis for this condition. Here we present two cases of young women with premature ovarian failure who were treated with glucocorticoids in the hopes of restoring fertility. The first case illustrates the potential benefit of such therapy, and the second case illustrates a potential risk. The first patient with histologically proven autoimmune oophoritis was treated with alternate day glucocorticoid treatment. She had return of menstrual bleeding six times and ovulatory progesterone concentrations four times over a 16 week period. The second patient with presumed but unconfirmed autoimmune ovarian failure was referred to us after having been treated with a 9 month course of corticosteroids. During that treatment her menses did not resume. The corticosteroid treatment was complicated by iatrogenic Cushing syndrome and osteonecrosis of the knee. Identifying patients with autoimmune premature ovarian failure presents the opportunity to restore ovarian function by treating these patients with the proper immune modulation therapy. On the other hand, potent immune modulation therapy can have major complications. Corticosteroid therapy for autoimmune premature ovarian failure should be limited to use in placebo-controlled trials designed to evaluate the safety and efficacy of such treatment. Key words: autoimmune lymphocytic oophoritis/autoimmune premature ovarian failure/glucocorticoids/osteonecrosis/return of ovarian function
Introduction
To restore fertility effectively for a young woman with autoimmune premature ovarian failure, the clinician needs first, a sensitive and specific non-invasive method to confirm that indeed the woman has ovarian failure on an autoimmune basis, and second, a treatment to administer that has been proven safe and effective by prospective randomized controlled trial.
At present, the clinician has neither of these (Nelson et al., 1996; Wheatcroft et al., 1997) . This makes autoimmune ovarian failure a frustrating condition for the young couples that it robs of fertility, and a frustrating condition for the clinicians that are caring for them. This frustration may lead to the use of empirical treatments, with which the potential benefits and risks are poorly defined. To bring focus to this issue, we present here two cases of young women with premature ovarian failure who were treated with glucocorticoids in the hopes of restoring fertility. The first case illustrates the potential benefit of such therapy, and the second case illustrates a potential risk.
Autoimmunity is a well established mechanism of ovarian failure (Irvine et al., 1968; Sedmak et al., 1987; Bannatyne et al., 1990) and, as a group, patients with karyotypically normal premature ovarian failure are known to have increased peripheral T lymphocyte activation (Rabinowe et al., 1986; Nelson et al., 1991) . On the other hand, simple elevated follicle stimulating hormone has been shown to be associated with increased peripheral T lymphocyte activation (Hoeck et al., 1995) . Nevertheless, increased numbers of activated peripheral T lymphocytes has been described in other autoimmune endocrine disorders, such as recent onset Grave's disease , insulin dependent diabetes mellitus (Jackson et al., 1982) and Addison's disease (Rabinowe et al., 1984) .
One percent of women by age 40 years spontaneously develop premature ovarian failure (Coulam et al., 1986) , a condition characterized by amenorrhoea, infertility, sex steroid deficiency, and elevated serum gonadotrophin concentrations (Rebar and Cedars, 1992; Nelson et al., 1996) . Anecdotal reports have suggested that glucocorticoid treatment may be useful in treating autoimmune premature ovarian failure (Cowchock et al., 1988; Taylor et al., 1989; Luborsky et al., 1990; Blumenfeld et al., 1993; Corenblum et al., 1993) .
Case reports

Case 1
A 26-year-old woman (gravida 2, para 1, abortus 1) presented to her private physician with acute abdominal pain and a right adnexal mass. At surgery, a 7 cm multiloculated cystic structure was removed from the right ovary. Histological examination revealed luteinized follicle cysts with dense lymphocytic infiltration. At age 28 years, the patient was referred to the National Institutes of Health Clinical Center.
Review of the slides showing the pathology confirmed the The patient had experienced menarche at age 10 years and had developed secondary sex characteristics appropriately. Her menses were regular every 28 days until she became pregnant at age 23 years. After the delivery of her only child she began taking oral contraceptives and became pregnant again at age 27 years while using this method. This pregnancy resulted in a spontaneous abortion and thereafter her menstrual cycles became irregular. Five months later the patient underwent emergency ovarian surgery. She subsequently developed amenorrhoea and experienced symptoms of sex steroid deficiency (hot flashes, vaginal dryness, and dyspareunia). Her serum gonadotrophin concentrations were found to be elevated [follicle stimulating hormone (FSH) 40 mIU/ml and luteinizing hormone (LH) 65 mIU/ml].
At age 29 years, she participated in a National Institute of Child Health and Human Development randomized, prospective, placebo-controlled trial of alternate-day prednisone for treatment of patients with histologically confirmed autoimmune 1778 ovarian failure. The protocol was approved by the National Institute of Child Health and Human Development Institutional Review Board. She received alternate day prednisone therapy for 16 weeks (mean daily dose of 11 mg, total cumulative dose of 1225 mg). During the prednisone treatment the patient resumed spontaneous menstrual bleeding six times and had ovulatory progesterone concentrations (Ͼ9.5 nmol/l) on four occasions. Her serum gonadotrophin concentrations decreased (Table I) . Subsequently, the Pharmacy Department informed us that the patient had been randomized to take the active drug.
Case 2
A 36-year-old nulligravida woman presented to her private physician complaining of infertility. Pertinent findings included vasomotor symptoms, amenorrhoea and elevated serum gonadotrophin concentrations. She had experienced menarche at age 13 years and had developed secondary sex characteristics appropriately; she had had regular 28 day menstrual cycles until age 34 years, when she began skipping menses. Her past medical history was significant for Hashimoto's thyroiditis (Weetman and McGregor, 1994) . With a presumptive but unconfirmed diagnosis of autoimmune premature ovarian failure, her private physician empirically prescribed a course of daily oral dexamethasone treatment. She took up to 2 mg of dexamethasone per day, resulting in a total dose of 255 mg over a 9 month period. During that time the patient gained 9 kg and developed a 'moon face'. Throughout that period her menses did not resume and she did not become pregnant. Furthermore, serum gonadotrophin concentrations remained elevated (FSH 69 mIU/ml and LH 46 mIU/ml). One month after stopping the dexamethasone treatment, the patient experienced right knee pain that was exacerbated by walking and other physical activity. The knee pain became severe and significantly altered her otherwise very active and athletic lifestyle. A magnetic resonance imaging scan of the right knee was consistent with osteonecrosis (i.e. non-traumatic necrosis of the bone) (Figure 2) . Arthroscopy confirmed the diagnosis, showing areas of osteonecrosis involving~30% of the medial femoral condyle and~15% of the medial tibial plateau.
At age 40 years, the patient was referred to the National Institutes of Health Clinical Center for assessment of her amenorrhoea. Laboratory evaluation confirmed the diagnosis of premature ovarian failure. It also revealed a normal karyotype, antithyroid antibodies at a titre of 1:400 (consistent with the earlier diagnosis of Hashimoto's thyroiditis), and antiparietal antibodies at a titre of 1:1280 (vitamin B 12 serum concentrations were normal). Other laboratory testing for autoimmune diseases was negative, including anti-ovarian antibodies (Luborsky et al., 1990) , rheumatoid factor, and antinuclear antibodies.
Discussion
Autoimmune premature ovarian failure is a frustrating disorder for patients and their physicians. To date there is no accurate serum marker available to identify patients who have premature ovarian failure due to autoimmunity (Wheatcroft et al., 1997) and the specific antigen involved in the development of autoimmune premature ovarian failure has yet to be discovered. Autoimmune diseases are characterized by the presence of histological inflammatory features, other coexisting autoimmune disorders, and circulating organ-specific autoantibodies (Pekonen et al., 1986; Muir and MacLaren, 1991; Hoek et al., 1997) . There is evidence suggesting the presence of ovarian antibodies in the sera of patients with premature ovarian failure (Coulam and Ryan, 1979) .
Ovarian biopsy is currently the only way to diagnose autoimmune premature ovarian failure with certainty. Nevertheless, there is no treatment proven effective by prospective, randomized, controlled study to restore fertility for these patients. Therefore, ovarian biopsy outside a controlled trial is not clinically indicated (Khastgir et al., 1994; Nelson et al., 1996) .
Young women with premature ovarian failure have intermittent ovarian follicle function (Rebar and Cedars, 1992; Nelson et al., 1994) and nearly 20% of these women ovulate spontaneously during 4 months of observation (Nelson et al., 1994) . Spontaneous pregnancies have occurred after the diagnosis of premature ovarian failure (Polansky and DePapp, 1976; Shangold et al., 1977; Szlachter et al., 1979; Aiman and Smentek, 1985; Ohsawa et al., 1985; Alper et al., 1986; Kreiner et al., 1988) and we have had patients who have ovulated after placebo treatment (Nelson et al., 1996) . Although autoimmune lymphocytic oophoritis is a known cause of premature ovarian failure, it is not known what proportion of women with premature ovarian failure develop the condition on an autoimmune basis. Indirect immunofluorescence using various sources of ovarian tissue (Damewood et al., 1986; Ho et al., 1988) and enzyme-linked immunosorbent assay (ELISA) (Luborsky et al., 1990; Gobert et al., 1992; Wheatcroft et al., 1994; Fenichel et al., 1997; Wheatcroft et al., 1997) have been the most commonly used techniques to identify ovarian antibodies. The two methods used for the detection of ovarian antibodies, indirect immunofluorescence and ELISA, were compared, and neither was found to be reliable (Wheatcroft et al., 1997) . Also, using ELISA, it was found that these antibodies are frequently detected in Turner's syndrome and iatrogenic ovarian failure as well (Wheatcroft et al., 1994) . Furthermore, ovarian antibodies detected by this method are non-specific, as they cross-react with other antigens such as those in the Fallopian tube (Wheatcroft et al., 1994) . In addition, immunoblotting studies failed to reveal a consistent pattern of binding using the sera of patients with premature ovarian failure on two antigen preparations (Wheatcroft et al., 1997) .
Steroid cell antibodies have been identified in patients with premature ovarian failure associated with Addison's disease (Elder et al., 1981; Uibo et al., 1994; Winqvist et al., 1995) . Nevertheless, steroid cell antibodies are not usually present in patients with isolated premature ovarian failure (Betterle et al., 1993; Weetman, 1995; Chen et al., 1996) .
Antibodies against membrane-bound receptors are known to cause diseases, such as myasthenia gravis (Lindstrom et al., 1976) and autoimmune hypothyroidism (Drexhage et al., 1981) . In addition, anti-FSH receptor antibodies, detected using animal systems, have been reported in a few patients with premature ovarian failure. We have found that immunoglobulin G (IgG) from patients with premature ovarian failure does not interfere with either the FSH-receptor or the LHreceptor interaction, using a recombinant system expressing human FSH and LH receptors (Anasti et al., 1995) .
Autoimmune lymphocytic oophoritis is characterized by a selective attack against only developing follicles with sparing of primordial follicles (Irvine et al., 1968; Sedmak et al., 1987; Bannatyne et al., 1990) . In most cases follicle development progresses to the Graafian stage. Autoimmune lymphocytic oophoritis sometimes presents with markedly enlarged ovaries containing luteinized cysts, as illustrated by the first case and as previously reported (Rabinowe et al., 1986) .
The defect in immune regulation that leads to autoimmune premature ovarian failure is not understood. Although most autoimmune diseases, such as multiple sclerosis, diabetes, and rheumatoid arthritis, appear to be T helper 1 (Th1) cell mediated, experimental data suggests that some autoimmune diseases, such as murine autoimmune post-thymectomy oophoritis and murine autoimmune encephalomyelitis, may be Th2 cell mediated (Lafaille et al., 1997; Maity et al., 1997) . The recent identification of a single gene defect on chromosome 21q22.3 causing autoimmune polyglandular failure type 1 (Nagamine et al., 1997; The Finnish-German APECED Consortium, 1997) , which in many cases includes autoimmune ovarian failure, may provide a basis for gaining insight into immune regulation and organ specific autoimmunity.
Anecdotal reports have suggested that glucocorticoid treatment may restore ovarian function in women with premature ovarian failure (Cowchock et al., 1988; Taylor et al., 1989; Luborsky et al., 1990; Blumenfeld et al., 1993; Corenblum et al., 1993) . There are presently no controlled studies, however, to tell us what proportion of women with autoimmune premature ovarian failure will ovulate in response to immune modulation therapy. More importantly, there are presently no controlled studies to tell us what proportion of women with autoimmune premature ovarian failure will have major com-plications in response to treatment with glucocorticoids. Glucocorticoid administration is the most frequent cause of osteonecrosis of the hip or knee (Mankin, 1992) . Pain is usually the presenting symptom of osteonecrosis, and the pain exacerbates with the use of the joint. The condition may be debilitating and require prosthetic hip or knee replacement (Mankin, 1992) . In fact, osteonecrosis accounts for~50 000 joint replacements performed annually in the USA (Mankin, 1992) . Iatrogenic Cushing syndrome is also a well-known major sequela of chronic corticosteroid administration (Zizic et al., 1985) .
The efficacy of treatment modalities should be documented by randomized controlled trials (Grimes, 1995) . A prospective randomized controlled study of alternate day prednisone therapy for autoimmune premature ovarian failure is now underway at the Clinical Center of the National Institutes of Health. This study will provide evidence for management decisions regarding patients with suspected autoimmune premature ovarian failure. In this study, since there is no diagnostic serum marker available, histological confirmation of the disease is a prerequisite for prednisone administration. We performed an ovarian biopsy when an antral follicle was detected on ultrasound in six patients with karyotypically normal spontaneous premature ovarian failure (Nelson et al., 1994) . Interestingly, we found no autoimmune oophoritis in any of these specimens (Nelson et al., 1994) .
The patient (case 1) presented in this case report did have histologically proven autoimmune oophoritis. While taking low-dose alternate day glucocorticoid treatment she had had return of menstrual bleeding six times and ovulatory progesterone concentrations four times over the 16 week period. Autoimmune premature ovarian failure is not a life threatening condition, so aggressive immunosuppression with glucocorticoids is not indicated. We developed our alternate day regimen dose with the objective of giving a dose that might have a beneficial effect yet be very unlikely to harm anyone. This case report suggests this regimen of prednisone given in an alternate day fashion might meet these objectives.
Identifying patients with autoimmune premature ovarian failure presents the opportunity to restore ovarian function by treating these patients with the proper immune modulation therapy. On the other hand, potent immune modulation therapy can have major complications. In our opinion, there is no role for empirical corticosteroid treatment of this disorder. There is need for an international collaborative research effort to make progress in this condition. In our view, immunosuppression by corticosteroids for the treatment of premature ovarian failure should be limited to patients with proven autoimmune oophoritis who are participating in placebo-controlled trials designed to determine safety and efficacy.
